Evotec achieves important milestone
TargetAD collaboration with Janssen in Alzheimer's disease
Evotec AG announced the achievement of an important milestone in its TargetAD collaboration with Janssen Pharmaceuticals, Inc. for the transition of a project into further drug discovery process. This milestone was reached in 2015 which will be recognised in the financial year 2015.
The agreement between Evotec and Janssen for this collaboration became effective on October 31, 2013. Johnson & Johnson Innovation, LLC facilitates the collaboration. Under the terms of the agreement, Janssen and Evotec continue to collaborate to develop new drugs for Alzheimer's disease. Janssen has the right to internalise selected targets and therapeutic candidates and progress them into pre-clinical and clinical development. Janssen funds target drug discovery research via a combination of defined research payments and progress-related milestones.
Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: "Despite the significant challenges in identifying and prosecuting novel targets in the field of Alzheimer's disease, our collaboration with Janssen continues to thrive as documented by this milestone. On the basis of an ever improving platform and an excellent team that is seamlessly integrated across both companies, we are confident that further progress will follow in 2016."
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Bracco Imaging and Shanghai Pharmaceuticals join forces in the field of ultrasound

Verder Group acquires ERWEKA - With this acquisition, Verder Scientific expands its portfolio to include dissolution and tablet testing equipment for the pharmaceutical and life science sectors
Primary_ciliary_dyskinesia
Evotec and CHDI Foundation, Inc. Extend Collaboration to Fight Huntington’s Disease
Leukocare appoints VP Business Development - Expands team and relocates operations to the IZB in Martinsried/Munich
Researchers trace HIV mutations that lead to drug resistance
Non-alcoholic_fatty_liver_disease
High-Tech Gruenderfonds invests in agricultural biotechnology startup
Anti-glycoprotein-210_antibodies
